These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1314286)

  • 1. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.
    Nowak T; Gregersen JP; Klockmann U; Cummins LB; Hilfenhaus J
    J Med Virol; 1992 Mar; 36(3):209-16. PubMed ID: 1314286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
    Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
    Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.
    Louie RE; Galloway CJ; Dumas ML; Wong MF; Mitra G
    Biologicals; 1994 Mar; 22(1):13-9. PubMed ID: 8068309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
    Dichtelmüller H; Rudnick D; Breuer B; Gänshirt KH
    Biologicals; 1993 Sep; 21(3):259-68. PubMed ID: 8117439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
    Hilfenhaus J; Gröner A; Nowak T; Weimer T
    Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective inactivation of a wide range of viruses by pasteurization.
    Gröner A; Broumis C; Fang R; Nowak T; Popp B; Schäfer W; Roth NJ
    Transfusion; 2018 Jan; 58(1):41-51. PubMed ID: 29148053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inactivation of BVDV (experimental model for hepatitis C) using low pH and heat treatment in intravenous human immunoglobulins].
    Ruibal Brunet IJ; Noa Romero E; Rivero Mas AT; Martín García RZ
    Sangre (Barc); 1999 Oct; 44(5):352-6. PubMed ID: 10618912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
    Hilfenhaus J; Geiger H; Lemp J; Hung CL
    J Biol Stand; 1987 Jul; 15(3):251-63. PubMed ID: 3649341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inactivation of viruses in Factor XIII concentrate by pasteurization].
    Mauler R; Hilfenhaus J
    Arzneimittelforschung; 1984; 34(11):1524-7. PubMed ID: 6543127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
    Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
    Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
    Morgenthaler JJ; Omar A
    Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
    Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
    Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulins: clinical experience and viral safety.
    Ballow M
    J Am Pharm Assoc (Wash); 2002; 42(3):449-58; quiz 458-9. PubMed ID: 12030632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
    Burnouf T
    Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.